命途多舛：曲妥珠单抗德鲁司坦获准上市后对肉瘤治疗的影响。

{"title":"命途多舛：曲妥珠单抗德鲁司坦获准上市后对肉瘤治疗的影响。","authors":"Brian C Schulte, Caleb Hwang, Andrew E Horvai, Timothee Olivier","doi":"10.1002/cncr.35539","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"When destiny doesn't pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan.\",\"authors\":\"Brian C Schulte, Caleb Hwang, Andrew E Horvai, Timothee Olivier\",\"doi\":\"10.1002/cncr.35539\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":138,\"journal\":{\"name\":\"Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cncr.35539\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cncr.35539","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}